I’m applying state-of-the-art molecular imaging techniques, e.g. Positron Emission Tomography (PET), for advancement of our understanding and management of different pathologies, in particular metabolic disease and cancer.
My current main research interests are:
I) non-invasive imaging methodologies for assessment of beta cell-mass in diabetes,
II) imaging markers for activated T-cells, for use in immuno-oncology and in the many diseases where inflammation is an important feature,
III) assisting drug development, by design of novel imaging based endpoints (e.g. in vivo mode of action, drug biodistribution),
IV) translational research, i.e. bringing radiopharmaceuticals from design and radiolabeling, via preclinical evaluation, to clinical proof-of-concept.
Olof Eriksson, Assistant Professor
Recruitments PhDs and postdocs ongoing (December 2018)
Eriksson O,Johnström P, Cselenyi Z, Jahan M, Selvaraju RK, Jensen-Waern M, Sörhede-Winzell M, Halldin C, Skrtic S, Korsgren O. In vivo visualization of beta cells by targeting of GPR44.Diabetes. 2018;67:182-192.
CarlbomL, Espes D, LubberinkM, Martinell M, JohanssonL, AhlströmH, CarlssonPO, Korsgren O, ErikssonO. [11C]5-hydroxy-tryptophan PET for assessment of islet mass during progression of type 2 diabetes. Diabetes. 2017;66:1286-1292.
Eriksson O, Mikkola K, Espes D, Tuominen L,Virtanen K, Forsbäck S, Haparanta-Solin M, Hietala J, Solin O, Nuutila P. The Cannabinoid Receptor-1 is an imaging biomarker of Brown Adipose Tissue. J Nucl Med. 2015;56:1937-41.
Selvaraju R, Velikyan I, Johansson L, Wu Z, Todorov I, Shively J, Kandeel F, Korsgren O, Eriksson O. In vivo imaging of the Glucagon Like Peptide-1 receptor in pancreas by [68Ga]DO3A-Exendin4. J Nucl Med. 2013;54:1458-63.
*Eich T, *Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007;356:2754-5. * The authors contributed equally